ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Effects of syringic acid on the indomethacin-induced gastric ulcer model in rats: in vivo and in silico study.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
In this study, the potential protective effects of syringic acid (SA) on gastric tissue were investigated in an indomethacin (INDO)-induced gastric ulcer model. A total of 84 male Sprague-Dawley rats were randomly divided into seven groups. In the in vivo experiments, rats were administered SA at doses of 5, 50, and 100 mg/kg and omeprazole (OMP) at a dose of 5 mg/kg intragastrically (i.g.) for 14 days, and indomethacin (100 mg/kg, i.g.) was administered on the final day. Following INDO administration, the rats were sacrificed under anesthesia, and gastric tissues were carefully excised for further analyses. The collected gastric tissues were subjected to biochemical, histopathological, and immunofluorescence analyses. In addition, in silico analyses were performed to support the INDO-induced gastric ulcer model. Using the licensed Schrödinger Maestro 2025/1 software, the binding properties of INDO to the COX-1 receptor were evaluated through molecular docking, MM-GBSA, and pharmacophore matching analyses. INDO administration was associated with oxidative stress, inflammation, apoptosis, and histopathological damage in gastric tissue. SA treatment appeared to alleviate INDO-induced gastric injury through its antioxidant, anti-inflammatory, and anti-apoptotic properties. SA treatment ameliorated histopathological alterations in ulcerated areas, particularly at doses of 50 and 100 mg/kg, whereas the 5 mg/kg dose did not show a significant protective effect. In addition, in silico analyses suggested that INDO may contribute to ulcer formation by inhibiting COX-1, thereby reducing prostaglandin production in the gastric mucosa. Overall, the findings of this study suggest that SA may reduce oxidative stress, suppress inflammatory responses, and inhibit apoptosis, thereby contributing to the protection of gastric tissue against INDO-induced injury. These results indicate that SA may have therapeutic potential for the prevention of NSAID-induced gastric injury; however, further experimental and clinical studies are needed to confirm these effects and clarify the underlying mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.